Background
Background to the litigation
Specifically, Orthotech seeks:·an order setting aside the Decision;·an order declaring that Orthotech is entitled, on payment of the ongoing listing fee, to have the Device included in the Prostheses List; and·costs.BACKGROUND Orthotech distributes orthopaedic implants for shoulders, hips and knees for use in surgical procedures in Australia. It also provides technical assistance to surgeons and other medical professionals in relation to procedures involving implants. At all material times Orthotech has been the distributor of the Device in Australia. The Device comprises a number of components and can be described as a mechanical shoulder replacement device. It is manufactured by JRI Limited, a British company. Orthotech distributes JRI Limited products in Australia. According to evidence of Mr Adrian Rowan, the general manager of Orthotech, in his affidavit sworn 5 February 2013, Orthotech has 154 prosthetic products on the Prostheses List, but distributes in Australia only one shoulder replacement device (namely, the Device). A delegate of the Minister made a decision on 5 January 2011 pursuant to section 72-10(5) of the Private Health Insurance Act 2007 (Cth) (“Private Health Insurance Act”) approving the inclusion of the Device on the Prostheses List. It is not in dispute that this decision was made following recommendations to the Minister that the Device be approved by the Specialist Orthopaedic Clinical Advisory Group (“SOCAG”) and the Prostheses List Advisory Committee (“PLAC”). SOCAG is a specialist advisory committee which provides advice and recommendations to PLAC, a higher level advisory committee established in October 2010 by the Minister to replace the Prostheses and Devices Committee (“PDC”). As explained by the departmental level guide “Prostheses List: Guide to listing and setting benefits for prostheses” (“the Guide”) published by the Department of Health and Ageing in July 2010, PLAC makes recommendations to the Minister on appropriate listing, and benefits, of prostheses on the Prostheses List. It appears that SOCAG recommended the Device be listed following a process of clinical evaluation of the Device by expert doctors in 2010. The expert doctors who assessed the Device were identified in correspondence as being (or including) Dr Graeme MacDougal and Dr Christopher Blenkin. Copies of extracts from documents marked “February 2011” and “PDC-in-confidence” are annexed to the affidavit of Ms Alexandra McVay, solicitor for Orthotech, sworn 25 February 2013. These documents relate to Orthotech’s applications pursuant to section 72-10(2) of the Private Health Insurance Act for approval of components of the Device. Annexure AKM-12 to Ms McVay’s affidavit records the clinical evaluation of one of the doctors prior to the final SOCAG recommendations in 2010 in relation to one of the components of the Device. The opinion of the doctor in respect of the component was:Suitable for listingEquivalent to comparators – based on the clinical information provided, this product is equivalent to the comparator(s) currently listed in the Prostheses List
Decision
Reasons for decision
SOCAG considered a further Orthotech submission at its meeting of 28 September 2012. At the PLAC meeting on 11 October 2012 members endorsed SOCAG’s recommendation, and agreed to recommend to the Minister that the Device be removed from the Prostheses List due to insufficient clinical evidence.The Decision The Decision was communicated in a letter dated 30 January 2013, signed by Mr David O’Neill of the Department. Materially the letter provided as follows:ORTHOTECH – VAIOS SHOULDER SYSTEM – PROSTHESES LISTI am writing to inform you that a decision has been made in relation to the prostheses that make up the VAIOS Shoulder System (specified below) and its continued listings in the Private Health Insurance (Prostheses) Rules 2012 (No 2) (the Rules). The decision was made by Fifine Cahill, Acting First Assistant Secretary, Medical Benefits Division.Ms Cahill has made the following decisions:To revoke, in accordance with section 330-20 of the Private Health Insurance Act 2007 (the Act) …. The listings in the Private Health Insurance (Prostheses) Rules 2012 (No 2) of the prostheses specified below by revoking, under subsection 72-10 of the Act …. The grants of the listings for those prostheses on 5 January 2011.Specified ProsthesesOrthotech Pty LtdOH 386 VAOIS Humeral Head Humeral Head 42-54 mmOrthotech Pty LtdOH390 VAOIS Reverse Humeral Insert Reverse Humeral Insert +0/6mmOrthotech Pty LtdOH387 VAIOS humeral neck Humeral Neck one sizeOrthotech Pty LtdOH388 VAIOS Humeral Stem Humeral Stem 8-16mmOrthotech Pty LtdOH385 VAIOS Cemented Glenoid Cemented Glenoid Sm&LgOrthotech Pty LtdOH383 VAIOS Glenoid Metal Back Glenoid Metal Back Sm&LgOrthotech Pty LtdOH389 VAIOS Humeral Metal Back Reverse Humeral Metal Back one sizeOrthotech Pty LtdOH384 VAIOS Glenoid Insert Glenoid insert Sm&LgOrthotech Pty LtdOH391 VAIOS Glenoid Dome Glenoid Dome 0,1.5mmOrthotech Pty LtdOH392 VAIOS Locking screw Locking screw one sizeIn anticipation of a request from you, a statement of reasons for this decision will be provided shortly. Detailed reasons for the Decision were provided by the Delegate on 8 February 2013. After identifying the material on which findings of fact were based, as well as those findings, Ms Cahill set out her Reasons for Decision as follows:55. In making my decision, I have considered:(a)The circumstances concerning the original recommendation and decision to grant the application to include the VAIOS Shoulder System on the list;(b)The review of that decision by the PLAC and the SOCAG and the expert advice from subsequent recommendation to revoke the original decision;(c)The Guide and the weight of expert opinion regarding high risk prostheses;(d)The submissions by or on behalf of Orthotech, including supporting documentation to those submissions, regarding the VAIOS Shoulder System; and(e)The expert analysis of the material contained in the Orthotech submissions and supporting documentation.56.The SOCAG initially assessed that the VAIOS Shoulder System was substantially clinically equivalent to a comparator. At the time, a clinical assessor had noted that there was no data provided specific to the VAIOS system such as two-year follow-up data, saying the sponsor used success of the comparator to justify listing.57.The SOCAG advises the PLAC that the VAIOS Shoulder System should be listed on the basis that it was equivalent to comparators, the PLAC recommended that the Minister list the VAIOS system components, and, after considering that advice, the delegate granted Orthotech’s application for listing.58.Subsequently, after reviewing that advice and recommendation, the SOCAG and the PLAC concluded, in essence, that the original recommendation was erroneous because it was inconsistent with important recommendations in the Guide. Specifically, the Guide contemplated that the device was of a type that is “high risk” and that the company should provide clinical proof of comparative efficacy and safety, with a minimum two-year follow-up.59.In that respect, I note that the Guide specifically sets a higher standard for evaluations for listing of high-risk devices and arthroplasties. This is the case even if those devices are otherwise substantially clinically equivalent to a comparator device. In particular, the Guide states that a device is to be treated as substantially clinically equivalent if, in comparison to comparators, it is not a high-risk prosthesis (eg, load bearing, articulating and/or a mobile implant). All arthroplasties are characterised as high-risk in the Guide.60.The Guide provides for evaluation of applications for listing of a prosthesis against two specific criteria, which can be summarised as follows:If the device is substantially clinically equivalent to a device already on the prostheses list, whether the comparator has demonstrated in clinical studies that the product is safe and effective over a period of time commensurate with its intended use, risk and likelihood of failure;If the device requires durability, is a high risk device, mobile load-bearing devices (arthroplasties) or new device using novel technology or design, whether there is clinical proof of efficacy and safety with a minimum two year follow-up for that device (page 32 of the Guide).I have taken account that the SOCAG and the PLAC make their recommendations based on the considerations set out in the Guide. The Guide was prepared with the input of experts in the field, including in the orthopaedic speciality, and contains relevant policy considerations which guide the exercise of my statutory discretion. However, I appreciate that the considerations in the Guide must not be inflexibly applied. I must be willing to depart from the Guide if the circumstances of the case require it. I have considered all of the submissions provided by or on behalf of Orthotech and am satisfied that it is appropriate to be guided by the provisions of the Guide.61.I accept and give weight to the expert opinion that all arthroplasties are “high risk” and therefore should be listed only when there is at least two years of follow-up data to demonstrate clinical efficiency and safety. I also accept expert advice from the SOCAG and the PLAC that the VAIOS device should be considered high risk. I have weighed this information against the information provided by Orthotech, including:·Orthotech’s belief that the VAIOS Shoulder System demonstrates clinical safety and efficacy from both a product viewpoint and from patient results achieved by surgeons;·The number of VAIOS surgeries since its introduction to the UK in April 2010. I note that Orthotech stated the system had been on the list for many months and had been used successfully by many doctors since that time. I have also noted that the VAIOS Shoulder System has been on the list since February 2011 and I am not aware of any particular safety or efficacy issues in relation to the device.·Orthotech considers that it has demonstrated ‘clinical proof of efficacy and safety, with a minimum of two years follow up’, providing a document titled Review of the Ongoing Listing of the VAIOS Shoulder System on the Prostheses List that includes a document titled ‘Clinical data … The 2 year Results – 30 August 2012’, prepared by Professor Wallace and a colleague, JRI test reports dated in 2009, articles or ‘project reports’ dated 2007 and 2008, a poster presentation for the EFORT Congress in May 2012 and an earlier version of the Review of the Ongoing Listing of the VAIOS Shoulder System on the Prostheses List, provided in September 2011.·The VAIOS device has been registered by the Therapeutic Goods Administration (a precondition to listing in the Rules).·That Orthotech considers it has provided extensive product details, design analysis, testing reports, clinical data including a poster presentation by Professor Wallace at the British Orthopaedic Association in September 2011 and that in its view, the VAIOS system had been “peer-reviewed”.·That Orthotech had claimed substantial clinical equivalence and provided the reasoning behind its claim, in its application for listing.·References from several surgeons who have used the device in Australia, stating there would have been more references but for the short timeframe for its submission.62.I note, however, that the PLAC also considered the additional information provided by Orthotech in August 2012. I accept the PLAC’s advice that the information provided does not demonstrate the comparative safety or efficacy of the VAIOS Shoulder System.63.I accept the advice from the PLAC and from SOCAG that the information provided by Orthotech does not include at least two years follow up data.64.I accept the PLAC’s advice that the information included literature on the Nottingham shoulder system and comparisons of it with the VAIOS Shoulder System and these comparisons only provided longer-term follow-up for the Nottingham system.65.I accept the PLAC’s advice that the two-year follow-up was conducted by the designer surgeon and the cohort (16) in the follow-up was small for a high-volume prosthesis. The prosthesis was used for several pathologies, making any analysis impossible.66.I also accept that the PLAC took into account in its evaluation that no peer-reviewed published data was provided by Orthotech.67.On balance, having regard to the PLAC’s advice, and the information provided by Orthotech, I am not satisfied that the VAIOS Shoulder System should continue to be listed in the Rules.68.I accept Orthotech’s advice that it would not have proceeded with the introduction of the VAIOS Shoulder System, and spent money doing so, if it had not been listed in the Rules in February 2011.69.I note I have no evidence regarding what benefit Orthotech may have gained from having the VAIOS Shoulder System listed for the past two years.70.I do not consider the expenditure incurred by Orthotech to be a sufficient reason to continue to list a high-risk prosthesis in the Rules.71.I note there is a potential detriment to patients (who could potentially face complications, leading to further surgery, and who would in turn make a subsequent claim on private health insurance) and private health insurers if the prostheses list includes high risk devices and those requiring long term durability with insufficient evidence of their comparable safety and efficacy. If prostheses are less safe or efficacious, this has the potential for a higher rate of revision surgery, which in turn places a greater financial demand on the private health industry as a result of the listing.72.Orthotech has stated that, if the VAIOS Shoulder System is removed from the prostheses list, then a person who requires subsequent revisionary surgery would not be able to have the VAIOS reverse shoulder operation and an entirely new shoulder system would have to be used.73.However, I am satisfied that removing the prosthesis from the list would not prevent the VAIOS Shoulder System from being used. The Rules do not regulate whether a prosthesis can be used, but set out the minimum benefit a private health insurer must pay in respect of a listed prosthesis if a privately insured person with insurance covering the provision of the prosthesis is provided with the prosthesis during hospital or hospital-substitute treatment.74.I accept that a privately insured person may be financially disadvantaged if their insurer would not pay any benefit for a prosthesis that is not listed.75.On balance, I do not consider the financial disadvantage that some people may incur if they have to have subsequent revisionary surgery after receiving the VAIOS Shoulder System to be sufficient reason to continue the listing of this prosthesis.THE RELEVANT LEGISLATIVE SCHEME UNDER THE PRIVATE HEALTH INSURANCE ACT